CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 49 enrolled
Drug / intervention
Recombinant hepatitis B vaccine with CpG adjuvantbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04456504
NCT04456504Phase 4Completed
CompareCT.gov

HepB-CpG Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders

University of Wisconsin, Madison·interventional·Posted Jul 2, 2020·Updated Jul 16, 2024

In Brief

A Phase 4 clinical trial evaluating Recombinant hepatitis B vaccine with CpG adjuvant for Healthcare Worker, Hepatitis B Vaccine, Nonresponder. Completed, enrolled 49 participants across 1 site.

Detailed Summary

This study is being done to determine if healthcare workers who have previously failed to respond to hepatitis B vaccine series will respond to a hepatitis B with CpG adjuvant (hepB-CpG) (Heplisav-B)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthcare Worker, Hepatitis B Vaccine, Nonresponder
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedJul 2, 2020
Enrollment StartSep 15, 2020
Primary CompletionDec 6, 2023
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 6 years ago

Interventions

Recombinant hepatitis B vaccine with CpG adjuvantbiological

Each participant will receive two doses of hepB-CpG separated by one month and blood draw to measure antibody to the hepatitis B surface antigen prior to dose 2 and one month after dose 2.